

Main Article

Alison Lim takes responsibility for the integrity of the content of the paper

Cite this article: Townsley R, Tan JY, Edy E, Lim A, McMahon J. A case series of interventions and outcomes in patients with laryngeal squamous cell cancer. *J Laryngol Otol* 2024;1–4. <https://doi.org/10.1017/S0022215124000707>

Received: 3 December 2023

Revised: 22 January 2024

Accepted: 5 February 2024

Keywords:


head and neck neoplasms; palliative care; tracheostomy; laryngeal neoplasms; quality of life

Corresponding author:

Alison Lim;

Email: alison.lim3@nhs.scot

A case series of interventions and outcomes in patients with laryngeal squamous cell cancer

Richard Townsley¹, Jiak Ying Tan², Elbert Edy³, Alison Lim⁴  and Jeremy McMahon^{4,5}

¹Department of Otorhinolaryngology, University Hospital Crosshouse, Kilmarnock, Scotland, UK, ²Department of Otorhinolaryngology, Glasgow Royal Infirmary, Glasgow, Scotland, UK, ³Department of Otorhinolaryngology, University of Glasgow, Glasgow, Scotland, UK, ⁴Department of Otorhinolaryngology, Queen Elizabeth University Hospital, Glasgow, Scotland, UK and ⁵Department of Maxillofacial Surgery, Queen Elizabeth University Hospital, Glasgow, Scotland, UK

Abstract

Objective. The larynx is the second most prevalent subsite for head and neck cancer. Over half of head and neck cancer patients present with advanced disease. We report our regional practices for palliative intent laryngeal squamous cell cancer (SCC).

Methods. Retrospective analysis of patients with laryngeal SCC treated with palliative intent, discussed at the regional head and neck multidisciplinary team meeting from July 2010 to June 2016.

Results. A total of 65 patients were included, of whom 45 per cent had potentially curable disease but were not fit for curative treatment. Nine patients (14 per cent) underwent tracheostomy, with mean survival and hospital stay of 278 and 48 days, respectively. Four patients (6 per cent) underwent debulking surgery with mean survival and hospital stay of 214 and 1 days, respectively.

Conclusion. All palliative treatment measures offered to patients can have an impact on survival and quality of life. Patients should be at the centre of the decision-making process and counselled on the potential impact of interventions.

Introduction

Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer in the world.¹ The larynx is the second most common subsite for head and neck SCC.² Approximately half of patients present with advanced stage disease, with around 60 per cent receiving palliative intent from the outset.^{3,4} Half of all head and neck SCC patients die from their disease and will require palliative input in some form.^{1,5} Of the variable subsites of head and neck SCC, laryngeal cancer has been reported as having the best five-year survival rate.⁶

Predicting outcomes in patients with head and neck SCC treated with palliative intent is fraught with difficulty because of the variable nature of why the decision to embark on the palliative pathway has been taken. Often reported outcomes are for patients with head and neck SCC as a single group,^{3,4} which therefore need to be interpreted with a degree of caution as head and neck cancers can include a range of subsite primaries and cancer pathologies. Reported survival has been reported to range from days to years.^{3,4,7}

There are several palliative interventions available to patients with laryngeal cancer, including open and trans-oral surgery, radiotherapy, chemotherapy and multi-modal interventions. A wide range of supportive measures are available to maintain and facilitate nutrition and communication, and manage symptom control. Any intervention will have risks that can negatively impact the patient's quality of life, including prolonged hospital stay or surgical complication. It is important to ensure a patient-centred plan is adopted and to ensure the patient's perspective and wishes are at the centre of the decision-making process.

This study aimed to elucidate our local practice and outcomes with regard to patients with laryngeal SCC managed with palliative intent from the outset. It is intended that this will better equip clinicians to communicate with patients regarding the palliative management of laryngeal SCC.

Methods

A retrospective analysis of all patients with a new diagnosis of laryngeal SCC presented between July 2010 and June 2016 at the South Glasgow and Clyde head and neck cancer multidisciplinary team (MDT) was undertaken. Patients whose treatment outcome was recorded as palliative intent were identified, and their electronic case records and case notes were reviewed. Clinical and demographic data were recorded. Patients who had undergone initial curative intent treatment but had subsequently been found to have residual disease on re-presentation to the MDT were excluded. Strengthening the

Table 1. Patient demographics

Demographic	Number of patients (n (%))
Gender	
– Male	52 (80)
– Female	13 (20)
Mean age	72
Smoking status	
– Current smoker	30 (46)
– Ex-smoker	22 (34)
– Non-smoker	6 (4)
– Unrecorded	7 (11)
Alcohol consumption	
– Abstinent	18 (28)
– Less than 14 units per week	7 (11)
– More than 14 units per week	21 (32)
– Previous alcohol dependence	8 (12)
– Unrecorded	11 (17)
Mean body mass index	21
Co-morbidity	
– Cardiovascular disease	34 (52)
– Chronic obstructive pulmonary disease	20 (31)
– Liver disease	3 (5)
– Kidney disease	7 (11)
– Diabetes	5 (8)
– Neurological disease	20 (31)
– Psychiatric disease	7 (11)
Performance status	
– 0	6 (9)
– 1	13 (20)
– 2	19 (29)
– 3	18 (29)
– 4	5 (8)
– Unrecorded	4 (6)
Previous malignancy	
– Lung	3 (5)
– Bladder	1 (2)
– Gastric	1 (2)
– Prostate	1 (2)
– Oesophagus	1 (2)
– Leukaemia	2 (3)
– Melanoma	1 (2)
– Renal	1 (2)
– Hepatocellular	1 (2)
– Nasopharynx	1 (2)
Previous head and neck squamous cell cancer (treatment completed over five years previously)	5 (8)
Stage	
– I	5 (8)

(Continued)

Table 1. (Continued.)

Demographic	Number of patients (n (%))
– II	8 (12)
– III	15 (23)
– IV	35 (54)
– Unrecorded	2 (3)
Subsite	
– Supraglottic	32 (49)
– Glottic	19 (29)
– Trans-glottic	12 (18)
– Subglottic	2 (3)

reporting of observational studies in epidemiology reporting guidelines were followed for the study.

Participants

A total of 406 patients with laryngeal SCC were referred to the South Glasgow and Clyde head and neck cancer MDT over the study period. Sixty-five patients had outcomes recorded indicating palliative intent treatment following initial MDT discussion and were included in the study.

Results

The demographic data for patients were collected and are displayed in [Table 1](#). In total, 80 per cent of patients ($n = 53$) were male with a mean age of 72, 46 per cent ($n = 30$) were current smokers and 32 per cent ($n = 21$) drank more than 14 units per week. The majority of patients had cardiovascular co-morbidities ($n = 34$, 52 per cent) and a performance status of 2 or more ($n = 42$, 65 per cent). In addition, 77 per cent of patients ($n = 50$) had advanced disease, stage III or IV, at MDT presentation.

Survival

At the time of the data collection one patient was still alive and the status of one patient was unknown. Mean survival time from presentation at the head and neck MDT was 211 days (standard deviation (SD) = 279; range, 1–1609 days). With the removal of outliers mean survival time was 143 days (SD = 148.2; range, 1–566 days).

Palliative management

All patients received best supportive care. Nine patients (14 per cent) were offered curative intent treatment, but following discussion with the patient, they declined this. Seventeen patients (26 per cent) had cancer which was deemed incurable and 10 (15 per cent) had a potentially curable cancer, but because of the presence of a second incurable malignancy were deemed palliative. In addition, 29 patients (45 per cent) had potentially curable disease, but because of medical co-morbidities they were not candidates for curative intent treatment.

[Table 2](#) outlines the interventions that were used for best supportive care. Nine patients (14 per cent) underwent

Table 2. Best supportive care treatment

Best supportive care	Number of patients (n (%))
Tracheostomy	9 (14)
Chemotherapy	3 (5)
Radiotherapy	2 (3)
Debulking	4 (6)
Enteral feeding tubes	11 (17)

tracheostomy and 3 (5 per cent) required their tracheostomy prior to discussion at the MDT. The mean time from tracheostomy to discharge was 48 days (range, 11–90 days). The mean time from tracheostomy insertion to death was 201 days (range, 42–232 days). The overall survival time from MDT for patients who underwent tracheostomy was a mean of 278 days (range, 63–1031 days). Four patients (6 per cent) underwent debulking surgery, with mean survival of 214 days and mean hospital stay of 1 day.

Discussion

Over the course of the study period, 16 per cent of patients referred to the MDT with laryngeal SCC embarked on a palliative pathway from the outset. This is comparable to other studies reporting rates of 20.8 per cent for oral cancer, 25 per cent for hypopharyngeal cancer and 21.5 per cent for head and neck cancer.^{3,8,9} The patients' co-morbidities had an impact on the decision-making process. Furthermore, 60 per cent of patients ($n = 39$) had potentially curative disease, but ultimately had palliative treatment due to significant co-morbidities or synchronous malignancies.

Overall, 54 per cent of patients ($n = 34$) presented with American Joint Committee on Cancer stage IV disease. This is lower than the reported rates for head and neck cancer as a whole.^{3,10} This may be because whilst in head and neck cancer the presenting symptoms can be non-specific, in laryngeal cancers, many patients present with voice change. There have been significant efforts to educate referring physicians of the potential for voice change to be a symptom of sinister pathology. Data from the English National Cancer audit have shown that hoarseness as a sole presenting symptom in laryngeal cancer reflected around 70 per cent of stage I–III disease,¹¹ therefore early referral of patients with persistent hoarseness may identify laryngeal cancer at a less advanced stage.

Risk factors for laryngeal cancer include smoking and alcohol consumption, which are also risk factors for respiratory and cardiovascular disease. It was found that 80 per cent of patients ($n = 52$) in this study were current or ex-smokers and most patients had cardiovascular co-morbidities ($n = 34$, 52 per cent). The treatment modalities for laryngeal SCC carry significant consequences and risk of complication. It is paramount that prior to embarking on a curative treatment pathway, the possible survival benefits are weighed up against the potentially negative impact on quality of life for the patient. Interruption to radiotherapy has been shown to be associated with a poorer prognosis in the treatment of head and neck cancer because it is thought that cancer cells may initially accelerate regrowth after the start of radiotherapy.¹²

Synchronous primaries were identified in 17 per cent of patients, with the most common being lung malignancy. This is consistent with other published data¹³ and is perhaps

expected with the common risk factors between laryngeal cancer and lung cancer.

Mean survival was 210 days. This is slightly longer than the mean survival times published for head and neck cancers as a whole.^{3,10} There was a wide range of survival times, which is most likely due to the heterogeneity of the reasons behind embarking on a palliative route. This illustrates the need for well-established support systems to be in place to help these patients through their journey.

Tracheostomy is an intervention that can secure the airway and provide symptomatic relief in airway obstruction. Our data show a longer mean survival in patients who had a tracheostomy, but also a mean hospital stay of 48 days following tracheostomy, with the associated long-term care consequences. In some of the non-tracheostomy cases, tracheostomy was deemed either inappropriate or the patient had refused tracheostomy. A common reason for patients to refuse tracheostomy was the concern that they may not be able to return home and would require either a care placement or to remain in hospital. In this case series, 8 of the patients (89 per cent) were discharged home or to a relative following their tracheostomy placement.

- It was found that 16 per cent of patients with laryngeal squamous cell cancer were treated with palliative intent from the outset
- In this study population, 54 per cent of patients presented with American Joint Committee on Cancer stage IV disease
- Forty-five per cent of patients in this study group treated with palliative intent had potentially curable disease
- Tracheostomy extended mean survival in the patient group, but necessitated a mean hospital stay of 42 days following tracheostomy insertion
- All potential interventions have an impact on a patient's quality of life and the patient must therefore be at the centre of the decision-making process

Debulking surgery had a mean hospital stay of 1 day and has been shown to negate the need for tracheostomy, with a low complication rate.^{14,15} Debulking surgery can be considered in patients with palliative laryngeal cancer who wish to minimise their hospital stay. It must be emphasised to the patient that this is a temporary measure due to tumour regrowth. In patients suitable for debulking, it is important to carry out careful decision making and a shared airway plan with anaesthetic colleagues.

Conclusion

Realistic medicine is the principle of putting the patient at the centre of the decision-making process. Patients should be involved in the decision-making process where they are able, and all efforts should be taken to provide them with the information needed to make informed decisions. This can be difficult as there is a lack of consensus on how best to manage patients with laryngeal cancer with palliative intent and there is a lack of research in this area. This, coupled with the fact that conversations about end-of-life and palliative care can be challenging and complex, means that the management of patients with palliative laryngeal cancer can be difficult. This case series demonstrates the management of laryngeal SCC in our centre and may help to inform clinicians and patients when making challenging decisions in the palliative setting.

Acknowledgments. Ms Moira Brook and Ms Eva Carson, MDT Coordinators, South Glasgow MDT.

Competing interests. None declared

References

- 1 Schenker Y, Arnold RM, Bauer JE. An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck cancer. *Cancer* 2015;**122**:340–3
- 2 Doobaree IU, Landis SH, Linklater KM, El-Hariry I, Moller H, Tyczynski J. Head and neck cancer in south east England between 1995–1999 and 2000–2004: an estimation of incidence and distribution by site, stage and histological type. *Oral Oncol* 2008;**45**:809–14
- 3 Begbie FD, Douglas CM, Finlay F, Montgomery J. Palliative intent treatment for head and neck cancer: an analysis of practice and outcomes. *J Laryngol Otol* 2019;**133**:313–17
- 4 Timon C, Reilly K. Head and neck mucosal squamous cell carcinoma: results of palliative management. *J Laryngol Otol* 2006;**120**:389–92
- 5 Nilsen ML, Johnson JT. Potential for low-value palliative care of patients with recurrent head and neck cancer. *Lancet Oncol* 2017;**18**:e284–9
- 6 Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by site of origin of the tumours. EURO CARE Working Group. *Eur J Cancer* 1998;**34**:2154–61
- 7 Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. *Eur J Cancer* 2000;**36**:1032–7
- 8 McMahon JD, Robertson GA, Liew C, McManners J, Mackenzie FR, Hislop WS *et al.* Oral and oropharyngeal cancer in the West of Scotland – long-term outcome data of a prospective audit 1999–2001. *Br J Oral Maxillofac Surg* 2011;**49**:92–8
- 9 Pracy P, Loughran S, Good J, Parmar S, Goranova R. Hypopharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol* 2016;**130**(suppl 2):104–10
- 10 Ledebroeer QCP, Van der Schroeff MP, Pruyn JFA, de Boer MF, Baatenburg de Jong RJ, van der Welden LA. Survival of patients with palliative head and neck cancer. *Head Neck* 2011;**33**:1021–6
- 11 Koo MM, Swann R, McPhail S, Abel GA, Elliss-Brookes L, Rubin GP *et al.* Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. *Lancet Oncol* 2020;**21**:73–9
- 12 Duncan W, MacDougall RH, Kerr GR, Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. *Radiother Oncol* 1996;**41**(3):203–7
- 13 Nikolaou AC, Markou CD, Petridis, Daniilidis IC. Second primary neoplasms in patients with laryngeal carcinoma. *Laryngoscope* 2000;**110**:58–64
- 14 Paleri V, Stafford FW, Sammut MS. Laser debulking in malignant upper airway obstruction. *Head Neck* 2005;**27**:296–301
- 15 Chan JY, To VS, Wong ST, Wei WI. Quality of dying in head and neck cancer patients: the role of surgical palliation. *Eur Arch Otorhinolaryngol* 2013;**270**:681–8